NewLimit

Working toward radical extension of human healthspan using epigenetic reprogramming.

NewLimit is a South San Francisco biotech developing mRNA medicines that reprogram the epigenome of aging cells to restore youthful function, with an initial focus on the liver. The company was founded in 2021 by Coinbase CEO and co-founder Brian Armstrong, former GV partner Blake Byers, and stem cell scientist Jacob Kimmel, who serves as CEO. The launch matters because NewLimit is moving from preclinical biology to the clinic faster than planned, raising $435 million in new funding in a Series C led by longtime supporter Founders Fund, joined by returners like Kleiner Perkins, Eli Lilly Ventures and Human Capital alongside newcomers Thrive Capital, Greenoaks and Quiet Capital . The lead program is a liver-targeted therapy delivered as fewer than ten transcription factors packaged inside a lipid nanoparticle in mRNA form , designed to reset the organ's biological age once the proteins are expressed inside hepatocytes. In preclinical work the candidate boosted regenerative capacity in old livers and made older mice more tolerant of alcohol. NewLimit plans to take it into a phase 1 trial next year, initially focused on patients who have fatty livers from a suite of sources, with phase 2 development then set to narrow in on alcohol-related liver disease . Beyond the liver, the company is finalizing transcription factor combos for two other cell types: endothelial cells within blood vessels and T cells , with chronic kidney disease and immune aging as follow-on targets. The thesis behind the raise is that reprogramming cell age is a tractable platform rather than a single drug, and that liver disease in older adults is a large enough first market to anchor a longevity company commercially while the broader healthspan work matures.

Tags

Comments (7)